Novavax Researcher Says No Chance Of A ‘Shortcut’ In Vaccine Safety

Three potential coronavirus vaccines are kept in a tray at Novavax labs in Gaithersburg, Md., in March 2020. The company has moved into phase 3 trials in the U.K.

Vaccine maker Novavax is starting a large coronavirus vaccine trial in the U.K. Gregory Glenn, the company’s president of research and development, talks with NPR about how vaccines are tested.

(Image credit: Andrew Caballero-Reynolds/AFP via Getty Images)

Read the full post on Health Care : NPR

James Doubek